Rasha Aboelhassan: Being the last speaker is a challenge, but usually, your exciting subject and professional presentation can make your job easier.
Rasha Aboelhassan, Senior Oncology Consultant at Nasser Institute Hospital for Research and Treatment, recently shared on LinkedIn:
“Being the last speaker after 2 days of exhausting discussions and interactive workshops at the International Medical Conference is a challenge, but usually, your exciting subject and professional presentation can make your job easier.
This is what I have learned from Harvard Training to Teach ( Medical School course training to teach).
Yesterday was my presentation in Onco Azhar about (maintenance immunotherapy
avelumab after induction chemotherapy for advanced TCC bladder cancer).
Although it was the last presentation after exhausting scientific Oncology meetings, most of the audience was really exhausted, but at the same time, excited about the subject: as they discussed all aspects of advanced urinary bladder carcinoma from epidemiology, treatment up to maintenance therapy and its cost benefit.
We discussed subgroup analyses of Javelin bladder 100: most of the oncologists were excited to know that even patients who reached CR after chemotherapy, good benefit from maintenance therapy by avelumab.
In the end, we asked ourselves: Can poor Egyptian patients really have this benefit of OS?
We beed real world data from Egypt.
But unfortunately there’s a little number of patients receiving this treatment: maintenance avelumab because of its high cost.”
Source: Rasha Aboelhassan/LinkedIn
-
17:28 29/11JeeSuk Chang: A multi-center trial - great efforts from the KROG team
-
17:00 29/11Maite Bourlon: Access to novel drugs for metastatic renal cell carcinoma is an unmet need in the Mexican population
-
23:17 28/11Manni Mohyuddin: Current trials must have observation/surveillance as control arm
-
23:04 28/11Juan P. Alderuccio: Our approach to secondary CNS involvement by aggressive lymphomas
-
17:17 27/11Vivek Subbiah: Treatment patterns and overall survival (OS) in patients with advanced NSCLC in three countries between 2011 and 2020
-
17:43 28/11Michele Carbone: The world is full of good, honest, nice people
-
17:24 28/11Jessica Clerc: Celebrating 90 Years of Excellence and Dedication in Cancer Care!
-
17:44 25/11Carlos Pedraz: Congratulations, Dr. Rafael Rosell for the very well deserved 2023 ISLB Lifetime Achievement Award
-
17:10 25/11100 Influential Celebrities in Oncology: The 2023 Edition – Part 4
-
13:34 24/11"Bald for a Cause" initiative - UWC Dilijan College
-
17:34 28/11The International Association of Cancer Registries annual conference - IARC
-
18:05 26/11Submit your abstract by 13 February for ESMO-Breast-24 - ESMO
-
17:58 26/11Lisa A. Lacasse: My sincere gratitude to the ACS CAN team, our incredible volunteers, and supporters for another outstanding year
-
16:47 16/11How social determinants can influence a patient’s ability to stay in treatment - ASCO
-
13:22 16/11SIOP Europe Student Summer School for Paediatric Oncology
-
17:25 29/11NIH Director’s Early Independence Award supports junior scientists to launch independent careers - National Cancer Institute
-
17:07 29/11Santhosh Kumar Devadas: I’m starting a new position as a Professor of Medical Oncology and Chief of Bone Marrow Transplant at Ramaiah Memorial Hospital and Ramaiah Medical College
-
16:48 27/11CRCHD seeks motivated scientists to serve as Program Directors - NCI Disparities
-
16:25 27/11Luisa Basset completed a fruitful nine-year tenure on the CCI board of trustees - Childhood Cancer International
-
18:14 26/11Tristan Knight: Attention hematology / oncology and pediatric hematology / oncology fellows